At the 2026 Science of Skin Summit, Allergan Aesthetics, a subsidiary of AbbVie, showcased its latest findings on aging, regenerative aesthetics, and exosome-based skincare. The company introduced the FACTS Principles, a scientific framework developed by SkinMedica®, aimed at ensuring consistent evaluation of exosome skincare products by focusing on formulation, stability, safety, and clinical evidence. This initiative seeks to enhance transparency and uphold rigorous scientific standards in the growing field of exosome skincare, which shows potential for improving skin longevity and biological function.
Read More
Allergan's research and development leaders highlighted insights from over 25 years of research and numerous clinical studies, underscoring the importance of evidence-based innovation in the skincare sector. Following Allergan Aesthetics' presentation, AbbVie Inc. (ABBV) stock remained stable on Pluang, priced at USD 261.69 with no change noted on September 15, 2026, at 19:14 WIB. The stock is close to its 52-week high of USD 265.97, signaling continued investor interest in AbbVie's innovations in the health sector.